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PALB2 is a breast cancer (BC) susceptibility gene. Its
product is the binding partner of BRCA1 and BRCA2
and is involved in DNA repair. Studies of multiple-case
BC families have reported that truncating mono-allelic
PALB2 mutations, on average, increase BC risk two to
six fold.
Our recent population-based study estimated that car-
riers of PALB2 c.3113G>A had a cumulative BC risk of
carrying PALB2 c.3113G>A to be 91% (95%CI=41-100)
by age 70, comparable to 65% (95%CI=44-78) and 45%
(95%CI=31-56) average risk estimates for BRCA1 and
BRCA2 mutation carriers respectively. One of these ped-
igrees used for the above estimation, extensively
screened but not found to carry a BRCA1 or BRCA2
mutation, exhibited ten diagnoses of BC, including five
under 50 years of age, and a pedigree structure that
does not allow for all cases to be explained by a single
genetic factor. In view of such a high risk estimate and
the observations of BC in non-PALB2 mutation carriers
in this and other pedigrees, we hypothesise that there
may be other genetic risk factors segregating through
this family.
Several genetic modifiers of BC risk have been verified
in BRCA1 and BRCA2 mutation carriers. Although these
genetic modifiers are associated with small changes in
risk individually, collectively they may account for con-
siderable risk modification for some women. Other
moderate to highly penetrant genetic factors could also
influence risk in BRCA1 and BRCA2 mutation carriers
and non-carriers in BC families harbouring such genetic
variants. Similarly, the presence of other genetic factors
in the subject PALB2 c.3113G>A pedigree of this study,
could alter the risk for mutation carriers and/or convey
BC risk to non-PALB2 mutation carriers. Such addi-
tional factors could further explain the multiple cases of
early onset BC and the high estimated risk of PALB2
c.3113G>A in this family.
Whole exome capture followed by massively parallel
sequencing was performed on four strategically selected
affected females of this family. We have shortlisted 15
variants in this family predicted to be protein damaging
by SIFT in genes with plausible relevance to cancer
aetiology. Eight such variants are predicted to result in
protein truncation or are variants predicted to have
strong effects on splicing efficiency, one of which have
been observed in key DNA repair genes. Six of the
genes have roles in DNA repair, three in cell cycle
checkpoint regulation, one controls telomerase activity
and another has been reported to be a prostate cancer
predisposition gene. Further analyses of these candidate
BC predisposition genes will be presented.
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